Emerald Mutual Fund Advisers Trust Boosts Stake in CeriBell, Inc. $CBLL

Emerald Mutual Fund Advisers Trust lifted its position in CeriBell, Inc. (NASDAQ:CBLL) by 58.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 155,360 shares of the company’s stock after purchasing an additional 57,175 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in CeriBell were worth $1,785,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in CBLL. Rhumbline Advisers boosted its holdings in shares of CeriBell by 26.5% in the first quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock valued at $300,000 after acquiring an additional 3,276 shares during the period. Peregrine Capital Management LLC purchased a new stake in CeriBell in the 2nd quarter valued at $6,399,000. Emerald Advisers LLC boosted its stake in CeriBell by 3.9% during the 2nd quarter. Emerald Advisers LLC now owns 125,869 shares of the company’s stock worth $2,358,000 after purchasing an additional 4,727 shares during the period. TimesSquare Capital Management LLC grew its position in CeriBell by 48.5% during the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after purchasing an additional 260,116 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in CeriBell by 55.4% in the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares during the period.

CeriBell Stock Down 1.7%

CBLL opened at $22.31 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $26.04. The stock has a market capitalization of $827.61 million, a P/E ratio of -14.77 and a beta of 1.02. The business has a 50 day simple moving average of $20.10 and a 200-day simple moving average of $15.37.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. On average, equities analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CBLL has been the subject of several recent research reports. BTIG Research reiterated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. Canaccord Genuity Group increased their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Insiders Place Their Bets

In related news, Director William W. Burke sold 32,728 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $22.02, for a total transaction of $720,670.56. Following the sale, the director owned 17,391 shares of the company’s stock, valued at approximately $382,949.82. The trade was a 65.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott Blumberg sold 36,000 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00. Following the completion of the transaction, the chief financial officer directly owned 118,842 shares of the company’s stock, valued at approximately $2,495,682. This trade represents a 23.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 375,212 shares of company stock worth $7,306,950. Insiders own 20.10% of the company’s stock.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.